Sector News

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

September 15, 2020
Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the U.K.

Announced over the weekend, the U.K. Big Pharma said its vaccine, known as AZD1222, “has resumed in the U.K. following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.”

It was halted at the start of last week over a serious safety concern. AstraZeneca was, and still is, keeping mum on the exact nature of what happened, but according to a New York Times report that cited a person familiar with the situation, a participant based in the U.K. was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.

In its statement over the weekend, AZ said it “cannot disclose further medical information” about why it halted, but added, “All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.”

The World Health Organization has cited AZD1222, a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that contains the genetic material of the SARS-CoV-2 virus spike protein, as a leading contender in the race for a vaccine.

Around 18,000 participants have had AZD1222 as part of the trial, AZ said.

While AZ and Oxford have been highlighted as race leaders, so too have Pfizer and BioNTech, which said they now want to boost their phase 2/3 trial for one of their five mRNA vaccines, BNT162b2, from around 30,000 to 44,000.

Also over the weekend, the companies said they have asked the FDA for the extra participants in order to include a broader patient population and with plans to include adolescents as young as 16 and people with chronic, stable HIV (human immunodeficiency viruses), hepatitis C or hepatitis B infection to “provide additional safety and efficacy data.”

It said it’s on track to hit its original target of 30,000 patients this week; despite wanting more people, Pfizer said in a statement that it was still on course to deliver data by the end of next month.

By: Ben Adams

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend